GLP-1 Medications and Type 1 Diabetes: What the Evidence Actually Shows Now
Follow on your favorite platform
She had lived with type 1 diabetes for more than twenty years. She was in her forties, running a household, building a career, and doing everything her care team had ever asked of her. When she read about GLP-1 medications and asked whether they might help, she was told no. Too risky. Not for type 1. She left that appointment believing the door was closed. It was not. The science had simply moved faster than the conversation in her exam room.
If you live with type 1 diabetes, or you love someone who does, you may have heard the same thing. For years, the standard answer about GLP-1 receptor agonists in type 1 was a cautious no. That caution was not irrational. But it was built on evidence that is now nearly a decade old, and the picture in 2026 looks very different.
Let me walk you through what actually changed.
This was such an important topic to bring to the podcast. If you prefer to watch or listen, you can catch the full episode on my channel.
The old "no" was real, but it was not the whole story
The original concern came from two trials published in 2016 that studied liraglutide, an older GLP-1 medication, in people with type 1 diabetes. They showed modest A1c improvements, meaningful weight loss, and lower insulin needs. They also raised real safety flags: more symptomatic low blood sugar and more episodes of high blood sugar with ketones at higher doses.
Here is the context that often gets left out. These studies did not require patients to have obesity. They enrolled lean patients least likely to benefit. Insulin was cut aggressively before and during the study. The drug used causes far more nausea than what we reach for today. And this was an era before continuous glucose monitors and automated insulin delivery were standard.
In other words, it was arguably the wrong patients, an older drug, and the wrong technology. The signal was real. It was not generalizable to how we practice now.
What The Newest Evidence Actually Shows
The conversation shifted with newer, better-designed research. A 2025 trial studied semaglutide in people who had type 1 diabetes and obesity while using an automated insulin delivery system. The result: improved time in range, marked weight loss, no diabetic ketoacidosis events, and severe low blood sugar rates similar to placebo. A smaller study of tirzepatide in adults with type 1 and a BMI over 30 showed similarly encouraging results.
Then came the real-world data. Large analyses of people living with type 1 found that GLP-1 use was linked to meaningfully fewer major cardiovascular events, less progression to end-stage kidney disease, lower overall mortality, and fewer hospitalizations. Critically, the rates of ketoacidosis and low blood sugar were similar between groups, the very fears that had kept this conversation off the table for years.
A lack of evidence is not the same as evidence that something does not work. The evidence is now here.
This Is Not For Everyone… And That Matters
Being evidence-based cuts both ways. These medications are not FDA approved for type 1 diabetes. Their use is off-label, and they are not right for every person who has type 1.
The 2026 standards of care now support GLP-1 use for obesity management in adults with type 1 who have a BMI of 30 or higher, through shared decision-making. People with cardiovascular risk factors, early kidney disease, or high insulin requirements appear to benefit most. This is also not appropriate for everyone: those with significant gastroparesis, untreated hypoglycemia unawareness, or recent ketoacidosis need those issues addressed first.
Why An Endocrinologist Is Not Optional Here
This is where the system tends to fail patients. A GLP-1 in type 1 diabetes is not a prescription you should receive at the end of a rushed visit with a six-month follow-up. It requires deliberate, individualized titration, proactive insulin adjustment as appetite and intake change, a clear sick-day plan, and continuous glucose monitoring that is not optional.
That kind of care takes time and expertise. It is exactly the kind of care a broken, volume-driven system makes harder to access. You deserve a physician who has the training to do this safely and the time to actually do it.
The Bottom Line
The evidence for GLP-1 receptor agonists in type 1 diabetes has crossed a meaningful threshold. We are not speculating anymore. For the right person, with the right monitoring and the right expertise, this can be powerful medicine.
The question is no longer whether the conversation is worth having. It is whether your care team is equipped to have it with you.
📍 Still have questions?
💬 Contact us and we'll be happy to help!
💌 Or join our newsletter to stay informed: Sign up here
FAQs
Are GLP-1 medications approved for type 1 diabetes? No. GLP-1 receptor agonists are approved for type 2 diabetes and obesity. Their use in type 1 is off-label, which means a knowledgeable physician may prescribe them based on evidence and clinical judgment, with careful monitoring.
If I have type 1, does this mean I should start a GLP-1? Not necessarily. The newest data supports having the conversation, especially if you have obesity, cardiovascular risk, early kidney disease, or high insulin requirements. Whether it is right for you is an individualized, shared decision with your endocrinologist.
Weren't these medications considered dangerous in type 1? Earlier concerns about low blood sugar and ketoacidosis came from 2016 trials with important limitations. Newer trials and large real-world analyses have not shown the same elevated risks, though monitoring still matters.
Do I need a continuous glucose monitor to do this safely? In our view, yes. Continuous glucose monitoring is what makes titrating a GLP-1 alongside insulin safe in type 1. If you are not on a CGM, that typically comes first.
Who should be cautious or avoid this? People with significant gastroparesis, untreated hypoglycemia unawareness, or recent diabetic ketoacidosis should address those issues before considering a GLP-1. This is always a shared decision.
How do I bring this up with my doctor? Ask directly: "Given my history, is a GLP-1 receptor agonist something we should be considering, and why or why not?" A provider equipped for this should be able to walk you through the risks, benefits, and monitoring plan.
